The treatment of depressed geriatric patients.
Biological changes more frequently associated with late onset depressions, such as cerebral arteriosclerosis, increased urinary MHPG concentrations, decreased gonadal functions, and increased MAO activity were reviewed and the therapeutic implications of these biological changes considered. The rationale for the use of Hydergine, amitriptyline, Gerovitol H3, fluoxymesterone, doxepin, and trazodone in geropsychiatric patients was discussed.
D000367:Age Factors; D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000378:metabolism / Q000627:therapeutic use; D001702:Biopharmaceutics; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism; D004088:Dihydroergotoxine / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000378:metabolism / Q000627:therapeutic use; D011343:Procaine / Q000627:therapeutic use
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D004088:Dihydroergotoxine; D011343:Procaine; D005474:Fluoxymesterone